December 19, 2023 10:33 AM ESTUpdated 10:44 AM
News Briefing

Kro­nos stops work on leukemia drug; Aldeyra shares ral­ly on eczema da­ta; Atavis­tik Bio's $40M

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Kro­nos Bio stops blood can­cer pro­gram: The biotech on Mon­day said Phase Ib da­ta of lan­raplenib in a mu­tat­ed sub­set of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times